Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 33 Million USD | -11.45% |
| 2022 | 36.49 Million USD | -29.38% |
| 2021 | 51.68 Million USD | 92.59% |
| 2020 | 26.83 Million USD | -32.82% |
| 2019 | 39.94 Million USD | -5.15% |
| 2018 | 42.1 Million USD | -0.4% |
| 2017 | 42.28 Million USD | -30.53% |
| 2016 | 60.86 Million USD | -9.48% |
| 2015 | 67.23 Million USD | 29.82% |
| 2014 | 51.79 Million USD | 27.58% |
| 2013 | 40.59 Million USD | 54.59% |
| 2012 | 26.25 Million USD | 13.97% |
| 2011 | 23.04 Million USD | 70.27% |
| 2010 | 13.53 Million USD | 148.51% |
| 2009 | 5.44 Million USD | 25.86% |
| 2008 | 4.32 Million USD | 90.72% |
| 2007 | 2.26 Million USD | -22.15% |
| 2006 | 2.91 Million USD | -0.26% |
| 2005 | 2.92 Million USD | 9.95% |
| 2004 | 2.65 Million USD | 18.29% |
| 2003 | 2.24 Million USD | -7.24% |
| 2002 | 2.42 Million USD | -33.59% |
| 2001 | 3.64 Million USD | -30.12% |
| 2000 | 5.21 Million USD | -23.9% |
| 1999 | 6.85 Million USD | 185.7% |
| 1998 | 2.4 Million USD | -27.27% |
| 1997 | 3.3 Million USD | 57.14% |
| 1996 | 2.1 Million USD | -19.23% |
| 1995 | 2.6 Million USD | 52.94% |
| 1994 | 1.7 Million USD | 112.5% |
| 1993 | 800 Thousand USD | 100.0% |
| 1992 | 400 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.08 Million USD | -7.67% |
| 2024 Q1 | 7.83 Million USD | -2.33% |
| 2023 Q1 | 8.9 Million USD | 5.41% |
| 2023 Q4 | 8.01 Million USD | 3.05% |
| 2023 Q2 | 8.12 Million USD | -8.83% |
| 2023 Q3 | 7.78 Million USD | -4.19% |
| 2023 FY | 32.31 Million USD | -11.45% |
| 2022 FY | 36.49 Million USD | -29.38% |
| 2022 Q3 | 8.01 Million USD | -6.51% |
| 2022 Q4 | 8.45 Million USD | 5.47% |
| 2022 Q1 | 11.45 Million USD | -60.48% |
| 2022 Q2 | 8.57 Million USD | -25.18% |
| 2021 Q3 | 8.06 Million USD | 8.98% |
| 2021 FY | 51.68 Million USD | 92.59% |
| 2021 Q4 | 28.99 Million USD | 259.73% |
| 2021 Q1 | 7.23 Million USD | 21.86% |
| 2021 Q2 | 7.39 Million USD | 2.28% |
| 2020 Q3 | 6.96 Million USD | 8.39% |
| 2020 FY | 26.83 Million USD | -32.82% |
| 2020 Q1 | 7.51 Million USD | -0.94% |
| 2020 Q4 | 5.93 Million USD | -14.8% |
| 2020 Q2 | 6.42 Million USD | -14.43% |
| 2019 Q1 | 12.87 Million USD | 25.88% |
| 2019 Q3 | 8.52 Million USD | -22.25% |
| 2019 Q4 | 7.58 Million USD | -11.07% |
| 2019 FY | 39.94 Million USD | -5.15% |
| 2019 Q2 | 10.96 Million USD | -14.82% |
| 2018 Q3 | 10.58 Million USD | 9.77% |
| 2018 FY | 42.1 Million USD | -0.4% |
| 2018 Q1 | 11.65 Million USD | 15.63% |
| 2018 Q4 | 10.22 Million USD | -3.4% |
| 2018 Q2 | 9.64 Million USD | -17.24% |
| 2017 Q1 | 11.58 Million USD | -3.72% |
| 2017 FY | 42.28 Million USD | -30.53% |
| 2017 Q4 | 10.07 Million USD | 1.55% |
| 2017 Q2 | 10.69 Million USD | -7.68% |
| 2017 Q3 | 9.92 Million USD | -7.2% |
| 2016 Q4 | 12.03 Million USD | 21.69% |
| 2016 Q1 | 24.11 Million USD | 9.11% |
| 2016 Q2 | 14.81 Million USD | -38.58% |
| 2016 Q3 | 9.88 Million USD | -33.26% |
| 2016 FY | 60.86 Million USD | -9.48% |
| 2015 Q1 | 13.8 Million USD | -5.62% |
| 2015 Q2 | 13.8 Million USD | 0.03% |
| 2015 Q4 | 22.1 Million USD | 26.23% |
| 2015 FY | 67.23 Million USD | 29.82% |
| 2015 Q3 | 17.51 Million USD | 26.83% |
| 2014 Q2 | 13.27 Million USD | 15.48% |
| 2014 Q3 | 12.45 Million USD | -6.23% |
| 2014 Q4 | 14.62 Million USD | 17.47% |
| 2014 Q1 | 11.49 Million USD | -10.69% |
| 2014 FY | 51.79 Million USD | 27.58% |
| 2013 Q3 | 10.54 Million USD | 24.71% |
| 2013 Q2 | 8.45 Million USD | -3.01% |
| 2013 Q1 | 8.72 Million USD | 17.6% |
| 2013 FY | 40.59 Million USD | 54.59% |
| 2013 Q4 | 12.87 Million USD | 22.03% |
| 2012 Q2 | 7.02 Million USD | 7.36% |
| 2012 Q1 | 6.54 Million USD | -7.67% |
| 2012 FY | 26.25 Million USD | 13.97% |
| 2012 Q3 | 6.78 Million USD | -3.54% |
| 2012 Q4 | 7.41 Million USD | 9.38% |
| 2011 Q3 | 5.37 Million USD | -6.3% |
| 2011 Q1 | 4.85 Million USD | -6.25% |
| 2011 Q2 | 5.73 Million USD | 18.27% |
| 2011 Q4 | 7.09 Million USD | 31.92% |
| 2011 FY | 23.04 Million USD | 70.27% |
| 2010 Q3 | 3.27 Million USD | 9.26% |
| 2010 Q1 | 2.09 Million USD | 312.62% |
| 2010 FY | 13.53 Million USD | 148.51% |
| 2010 Q2 | 2.99 Million USD | 43.11% |
| 2010 Q4 | 5.17 Million USD | 58.08% |
| 2009 Q1 | 1.2 Million USD | -3.61% |
| 2009 Q2 | 1.53 Million USD | 27.46% |
| 2009 Q4 | -984.5 Thousand USD | -129.12% |
| 2009 Q3 | 3.38 Million USD | 119.6% |
| 2009 FY | 5.44 Million USD | 25.86% |
| 2008 Q4 | 1.25 Million USD | -6.52% |
| 2008 Q1 | 788.09 Thousand USD | 27.95% |
| 2008 Q3 | 1.34 Million USD | -1.41% |
| 2008 Q2 | 1.35 Million USD | 72.56% |
| 2008 FY | 4.32 Million USD | 90.72% |
| 2007 Q4 | 615.91 Thousand USD | 59.22% |
| 2007 Q2 | 504.53 Thousand USD | -33.73% |
| 2007 Q1 | 761.33 Thousand USD | -7.18% |
| 2007 FY | 2.26 Million USD | -22.15% |
| 2007 Q3 | 386.82 Thousand USD | -23.33% |
| 2006 Q2 | 784.37 Thousand USD | 11.61% |
| 2006 Q4 | 820.2 Thousand USD | 35.24% |
| 2006 Q3 | 606.48 Thousand USD | -22.68% |
| 2006 Q1 | 702.81 Thousand USD | 2.69% |
| 2006 FY | 2.91 Million USD | -0.26% |
| 2005 FY | 2.92 Million USD | 9.95% |
| 2005 Q1 | 916.6 Thousand USD | 15.83% |
| 2005 Q2 | 676.44 Thousand USD | -26.2% |
| 2005 Q3 | 644.13 Thousand USD | -4.78% |
| 2005 Q4 | 684.42 Thousand USD | 6.25% |
| 2004 Q4 | 791.33 Thousand USD | 34.96% |
| 2004 Q1 | 636.19 Thousand USD | 1.53% |
| 2004 Q2 | 643.28 Thousand USD | 1.11% |
| 2004 Q3 | 586.33 Thousand USD | -8.85% |
| 2004 FY | 2.65 Million USD | 18.29% |
| 2003 Q1 | 562.3 Thousand USD | -29.01% |
| 2003 FY | 2.24 Million USD | -7.24% |
| 2003 Q3 | 467.19 Thousand USD | -20.84% |
| 2003 Q2 | 590.17 Thousand USD | 4.96% |
| 2003 Q4 | 626.58 Thousand USD | 34.12% |
| 2002 Q3 | 403.44 Thousand USD | -36.38% |
| 2002 Q4 | 792.13 Thousand USD | 96.34% |
| 2002 FY | 2.42 Million USD | -33.59% |
| 2002 Q1 | 591.97 Thousand USD | 21.85% |
| 2002 Q2 | 634.1 Thousand USD | 7.12% |
| 2001 Q2 | 1.15 Million USD | 16.6% |
| 2001 Q1 | 990.88 Thousand USD | -10.9% |
| 2001 Q3 | 970.5 Thousand USD | -16.0% |
| 2001 FY | 3.64 Million USD | -30.12% |
| 2001 Q4 | 485.82 Thousand USD | -49.94% |
| 2000 Q3 | 1.3 Million USD | -6.61% |
| 2000 FY | 5.21 Million USD | -23.9% |
| 2000 Q1 | 1.4 Million USD | -9.83% |
| 2000 Q2 | 1.39 Million USD | -0.45% |
| 2000 Q4 | 1.11 Million USD | -14.78% |
| 1999 Q2 | 1.7 Million USD | 41.67% |
| 1999 Q1 | 1.2 Million USD | 0.0% |
| 1999 FY | 6.85 Million USD | 185.7% |
| 1999 Q4 | 1.55 Million USD | -35.14% |
| 1999 Q3 | 2.4 Million USD | 41.18% |
| 1998 Q1 | 1.3 Million USD | 0.0% |
| 1998 FY | 2.4 Million USD | -27.27% |
| 1998 Q3 | 1.3 Million USD | 18.18% |
| 1998 Q2 | 1.1 Million USD | -15.38% |
| 1997 FY | 3.3 Million USD | 57.14% |
| 1997 Q1 | 600 Thousand USD | -25.0% |
| 1997 Q4 | 1.3 Million USD | 8.33% |
| 1997 Q3 | 1.2 Million USD | 0.0% |
| 1997 Q2 | 1.2 Million USD | 100.0% |
| 1996 Q2 | -2.1 Million USD | 0.0% |
| 1996 Q3 | 700 Thousand USD | 133.33% |
| 1996 Q4 | 800 Thousand USD | 14.29% |
| 1996 FY | 2.1 Million USD | -19.23% |
| 1996 Q1 | - USD | 0.0% |
| 1995 Q3 | 300 Thousand USD | -62.5% |
| 1995 Q4 | - USD | -100.0% |
| 1995 Q2 | 800 Thousand USD | 33.33% |
| 1995 Q1 | 600 Thousand USD | -14.29% |
| 1995 FY | 2.6 Million USD | 52.94% |
| 1994 Q1 | 300 Thousand USD | 50.0% |
| 1994 FY | 1.7 Million USD | 112.5% |
| 1994 Q3 | 500 Thousand USD | -16.67% |
| 1994 Q2 | 600 Thousand USD | 100.0% |
| 1994 Q4 | 700 Thousand USD | 40.0% |
| 1993 Q1 | 200 Thousand USD | 0.0% |
| 1993 Q3 | 200 Thousand USD | 0.0% |
| 1993 Q4 | 200 Thousand USD | 0.0% |
| 1993 FY | 800 Thousand USD | 100.0% |
| 1993 Q2 | 200 Thousand USD | 0.0% |
| 1992 Q2 | 200 Thousand USD | 100.0% |
| 1992 FY | 400 Thousand USD | 0.0% |
| 1992 Q4 | 200 Thousand USD | 0.0% |
| 1992 Q1 | 100 Thousand USD | 0.0% |
| 1992 Q3 | 200 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | -2.902% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -256.139% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -183.346% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 36.526% |
| Azitra, Inc. | 8.3 Million USD | -297.56% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -269.288% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -380.991% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | -13.849% |
| CEL-SCI Corporation | 31.47 Million USD | -4.864% |
| iBio, Inc. | 16.85 Million USD | -95.783% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -63.544% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | -32.761% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -136.922% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -155.908% |
| NanoViricides, Inc. | 8.51 Million USD | -287.583% |
| Oragenics, Inc. | 5.45 Million USD | -505.416% |
| BiomX Inc. | 26.81 Million USD | -23.096% |
| BiomX Inc. | 26.81 Million USD | -23.096% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | -2.98% |
| Palatin Technologies, Inc. | 34.67 Million USD | 4.798% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 17.101% |